Cargando…

Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation

INTRODUCTION: Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. CASE PRESENTATION: A 57‐year‐old woman was diagnosed with left rena...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambe, Takanari, Yamasaki, Toshinari, Mine, Yuta, Hagimoto, Hiroki, Kokubun, Hidetoshi, Kubota, Masashi, Tsutsumi, Naofumi, Inoue, Koji, Hara, Shigeo, Kawakita, Mutsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057747/
https://www.ncbi.nlm.nih.gov/pubmed/35509785
http://dx.doi.org/10.1002/iju5.12427
_version_ 1784697969831837696
author Kambe, Takanari
Yamasaki, Toshinari
Mine, Yuta
Hagimoto, Hiroki
Kokubun, Hidetoshi
Kubota, Masashi
Tsutsumi, Naofumi
Inoue, Koji
Hara, Shigeo
Kawakita, Mutsushi
author_facet Kambe, Takanari
Yamasaki, Toshinari
Mine, Yuta
Hagimoto, Hiroki
Kokubun, Hidetoshi
Kubota, Masashi
Tsutsumi, Naofumi
Inoue, Koji
Hara, Shigeo
Kawakita, Mutsushi
author_sort Kambe, Takanari
collection PubMed
description INTRODUCTION: Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. CASE PRESENTATION: A 57‐year‐old woman was diagnosed with left renal cell carcinoma and lung carcinomatous lymphangiosis (cT3aN0M1). After receiving combined immunotherapy, she achieved complete response for the lung metastases and partial response for the primary tumor. After five months of systemic therapy, she underwent partial nephrectomy to remove the primary tumor, followed by eight courses of nivolumab monotherapy. One year postoperatively, she remained recurrence‐free. CONCLUSION: Cytoreductive partial nephrectomy for surgical consolidation may be a treatment option for metastatic renal cell carcinoma.
format Online
Article
Text
id pubmed-9057747
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90577472022-05-03 Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation Kambe, Takanari Yamasaki, Toshinari Mine, Yuta Hagimoto, Hiroki Kokubun, Hidetoshi Kubota, Masashi Tsutsumi, Naofumi Inoue, Koji Hara, Shigeo Kawakita, Mutsushi IJU Case Rep Case Reports INTRODUCTION: Cytoreductive nephrectomy has been used in combination with systemic therapy for the treatment of metastatic renal cell carcinoma, although its efficacy in the era of immune checkpoint inhibitors remains controversial. CASE PRESENTATION: A 57‐year‐old woman was diagnosed with left renal cell carcinoma and lung carcinomatous lymphangiosis (cT3aN0M1). After receiving combined immunotherapy, she achieved complete response for the lung metastases and partial response for the primary tumor. After five months of systemic therapy, she underwent partial nephrectomy to remove the primary tumor, followed by eight courses of nivolumab monotherapy. One year postoperatively, she remained recurrence‐free. CONCLUSION: Cytoreductive partial nephrectomy for surgical consolidation may be a treatment option for metastatic renal cell carcinoma. John Wiley and Sons Inc. 2022-03-25 /pmc/articles/PMC9057747/ /pubmed/35509785 http://dx.doi.org/10.1002/iju5.12427 Text en © 2022 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Kambe, Takanari
Yamasaki, Toshinari
Mine, Yuta
Hagimoto, Hiroki
Kokubun, Hidetoshi
Kubota, Masashi
Tsutsumi, Naofumi
Inoue, Koji
Hara, Shigeo
Kawakita, Mutsushi
Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title_full Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title_fullStr Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title_full_unstemmed Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title_short Complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
title_sort complete remission of renal cell carcinoma with lung carcinomatous lymphangiosis after primary therapy with immune checkpoint inhibitors followed by partial nephrectomy for surgical consolidation
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057747/
https://www.ncbi.nlm.nih.gov/pubmed/35509785
http://dx.doi.org/10.1002/iju5.12427
work_keys_str_mv AT kambetakanari completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT yamasakitoshinari completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT mineyuta completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT hagimotohiroki completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT kokubunhidetoshi completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT kubotamasashi completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT tsutsuminaofumi completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT inouekoji completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT harashigeo completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation
AT kawakitamutsushi completeremissionofrenalcellcarcinomawithlungcarcinomatouslymphangiosisafterprimarytherapywithimmunecheckpointinhibitorsfollowedbypartialnephrectomyforsurgicalconsolidation